Phototherapy as a First Line Treatment for Mycosis Fungoides: A 10-year Retrospective Study
Introduction: Phototherapy, particularly psoralen plus ultraviolet A (PUVA) and narrowband ultraviolet B (nbUVB), is a mainstay in the treatment of Mycosis Fungoides (MF).
Methods: We analyzed outcomes of MF patients treated for the first time with either PUVA or nbUVB at the Photodermatology Unit, in the Department of Dermatology of Centro Hospitalar Universitário do Porto, from 2007 to 2017. The primary outcome was response to treatment. The secondary outcome was disease relapse free survival.
Results: From a total number of 34 patients with MF identified, nine (26.5%) patients were diagnosed at stage IA and 25 (73.5%) patients were diagnosed at stage IB. Of these patients, 30 (88.2%) were treated with PUVA and four (11.8%) with nbUVB. Overall, 24 (80%) patients treated with PUVA and two (50%) patients treated with nbUVB had complete responses (CR). Relapse was observed in 17 (70.8%) PUVA treated patients and two (100%) nbUVB treated patients. Median disease relapse free survival was 12 months for PUVA and 6 months for nbUVB.
Conclusion: PUVA is an effective therapy in early MF. Narrowband UVB could be a valid therapeutic alternative for these patients. However, the small size of nbUVB group in our study limits the conclusions about its efficacy.
Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2018 Oct;29(Supplement_4):iv30–40. doi: 10.1093/annonc/mdy133
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005 May;105(10):3768–85. doi: 10.1182/blood-2004-09-3502
Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007 Sep;110(6):1713–22. doi: 10.1182/blood-2007-03-055749
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240–2. doi: 10.1016/j.jaad.2013.07.049
Olsen EA, Hodak E, Anderson T, Carter JB, Henderson M, Cooper K, et al. Guidelines for phototherapy of mycosis fungoides and Sezary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016 Jan;74(1):27–58. doi: 10.1016/j.jaad.2015.09.033
Grandi V, Fava P, Rupoli S, Alberti Violetti S, Canafoglia L, Quaglino P, et al. Standardization of regimens in Narrowband UVB and PUVA in early stage mycosis fungoides: position paper from the Italian Task Force for Cutaneous Lymphomas. J Eur Acad Dermatol Venereol. 2018 May;32(5):683–91. doi: 10.1111/jdv.14668
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011 Jun;29(18):2598–607. doi: 10.1200/JCO.2010.32.0630
Gilchrest BA, Parrish JA, Tanenbaum L, Haynes HA, Fitzpatrick TB. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer. 1976 Aug;38(2):683–9.
Diederen PVMM, van Weelden H, Sanders CJG, Toonstra J, van Vloten WA. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol. 2003 Feb;48(2):215–9. doi: 10.1067/mjd.2003.80
El-Mofty M, El-Darouty M, Salonas M, Bosseila M, Sobeih S, Leheta T, et al. Narrow band UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early-stage mycosis fungoides: a right-left comparative study. Photodermatol Photoimmunol Photomed. 2005 Dec;21(6):281–6. doi: 10.1111/j.1600-0781.2005.00183.x
Wackernagel A, Hofer A, Legat F, Kerl H, Wolf P. Efficacy of 8-methoxypsoralen vs. 5-methoxypsoralen plus ultraviolet A therapy in patients with mycosis fungoides. Br J Dermatol. 2006 Mar;154(3):519–23. doi: 10.1111/j.1365-2133.2005.07008.x
Ponte P, Serrao V, Apetato M. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J Eur Acad Dermatol Venereol. 2010 Jun;24(6):716–21. doi: 10.1111/j.1468-3083.2009.03500.x
Hernandez Z, Penate Y, Hernandez-Machin B, Perez-Mendez L, Suarez-Hernandez J, Hernandez J, et al. Treatment of stage Ia and Ib mycosis fungoides with psoralen UVA monotherapy: an observational study in tertiary hospitals in the Canary Islands. Int J Dermatol. 2014 Nov;53(11):1417–22. doi: 10.1111/ijd.12425
Nikolaou V, Sachlas A, Papadavid E, Economidi A, Karambidou K, Marinos L, et al. Phototherapy as a first-line treatment for early-stage mycosis fungoides: The results of a large retrospective analysis. Photodermatol Photoimmunol Photomed. 2018 Sep;34(5):307–13. doi: 10.1111/phpp.12383
Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol. 1999 Nov;135(11):1377–80.
Gathers RC, Scherschun L, Malick F, Fivenson DP, Lim HW. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol. 2002 Aug;47(2):191–7.
Almohideb M, Walsh S, Walsh S, Shear N, Alhusayen R. Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto. Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):604–12. doi: 10.1016/j.clml.2017.06.015
Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013 Feb;133(2):377–85. doi: 10.1038/jid.2012.339
Ghodsi SZ, Hallaji Z, Balighi K, Safar F, Chams-Davatchi C. Narrow-band UVB in the treatment of early stage mycosis fungoides: report of 16 patients. Clin Exp Dermatol. 2005 Jul;30(4):376–8. doi: 10.1111/j.1365-2230.2005.01840.x
Boztepe G, Sahin S, Ayhan M, Erkin G, Kilemen F. Narrowband ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides. J Am Acad Dermatol. 2005 Aug;53(2):242–6. doi: 10.1016/j.jaad.2005.03.012
Gokdemir G, Barutcuoglu B, Sakiz D, Koslu A. Narrowband UVB phototherapy for early-stage mycosis fungoides: evaluation of clinical and histopathological changes. J Eur Acad Dermatol Venereol. 2006 Aug;20(7):804–9. doi: 10.1111/j.1468-3083.2006.01635.x
Pavlotsky F, Barzilai A, Kasem R, Shpiro D, Trau H. UVB in the management of early stage mycosis fungoides. J Eur Acad Dermatol Venereol. 2006 May;20(5):565–72. doi: 10.1111/j.1468-3083.2006.01557.x
Brazzelli V, Antoninetti M, Palazzini S, Prestinari F, Borroni G. Narrow-band ultraviolet therapy in early-stage mycosis fungoides: study on 20 patients. Photodermatol Photoimmunol Photomed. 2007 Dec;23(6):229–33. doi: 10.1111/j.1600-0781.2007.00314.x
Dereure O, Picot E, Comte C, Bessis D, Guillot B. Treatment of early stages of mycosis fungoides with narrowband ultraviolet B. A clinical, histological and molecular evaluation of results. Dermatology. 2009;218(1):1–6. doi: 10.1159/000161114
Abel EA, Sendagorta E, Hoppe RT, Hu CH. PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study. Arch Dermatol. 1987 Jul;123(7):897–901.
Querfeld C, Rosen ST, Kuzel TM, Kirby KA, Roenigk HHJ, Prinz BM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005 Mar;141(3):305–11. doi: 10.1001/archderm.141.3.305
Copyright (c) 2019 Journal of the Portuguese Society of Dermatology and Venereology
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles in this journal are Open Access and meet the requirements of funding bodies or academic institutions. Each article published in the Journal is published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). Articles can be read, downloaded, printed, and shared.
Submission of an article for publication implies the authors’ consent to publication under the applicable Creative Commons license and the terms and conditions of the Publisher’s Licensing Agreement.
It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement'. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Author rights: As an author you (or your employer or institution) have certain rights to reuse your work.
The Journal reserves the right to use plagiarism detection software on any submitted material.